The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises 1-methylxanthine and optionally other compounds that modulate the effects of 1-methylxanthine. Uses for the 1-methylxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
The disclosed compositions, systems and methods relate to compositions for human consumption and comprise a combination of paraxanthine and/or 1-methylxanthine and chlorogenic acid and optionally other compounds that modulate the effects of a combination of paraxanthine and/1-methylxanthine and chlorogenic acid. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of cognitive performance, mood, and/or sleep.
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The disclosed compositions, systems and methods relate to compositions for human consumption and comprise a combination of paraxanthine and/or 1-methylxanthine and chlorogenic acid and optionally other compounds that modulate the effects of a combination of paraxanthine and/1-methylxanthine and chlorogenic acid. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of cognitive performance, mood, and/or sleep.
The disclosed technology relates generally to compositions, methods, and system for utilizing paraxanthine alone and in combination for use in enhancing immune function and/or inhibiting inflammation through administration of a paraxanthine-containing composition to a subject. More particularly, the disclosure relates to paraxanthine and other compounds, whether produced synthetically or derived from natural sources, and use of these compounds to provide physiological benefits, which may vary according to paraxanthine concentration and the presence of synergists and antagonists.
The disclosed technology relates generally to compositions, methods, and system for utilizing paraxanthine alone and in combination for use in enhancing immune function and/or inhibiting inflammation through administration of a paraxanthine-containing composition to a subject. More particularly, the disclosure relates to paraxanthine and other compounds, whether produced synthetically or derived from natural sources, and use of these compounds to provide physiological benefits, which may vary according to paraxanthine concentration and the presence of synergists and antagonists.
The disclosed compositions and methods relate to compositions for human consumption comprising paraxanthine and a cholinergic agent and/or theanine. The disclosed compositions are useful for promoting cognitive function, energy, athletic performance and providing neuroprotective anti-oxidative effects.
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises a combination of paraxanthine and tyrosine and/or taurine and optionally other compounds that modulate the effects of a combination of paraxanthine and tyrosine and/taurine. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
The disclosed compositions methods relate to a dietary supplement for subjects with slow caffeine metabolism and comprises paraxanthine and optionally other compounds that modulate the effects of paraxanthine. Uses for the paraxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite in a slow caffeine metabolizer subject.
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61P 25/00 - Drugs for disorders of the nervous system
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/205 - Amine addition salts of organic acidsInner quaternary ammonium salts, e.g. betaine, carnitine
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutraceuticals for use as a dietary supplement; dietary
supplements; nutraceuticals for use as an ingredient in the
manufacture of dietary supplements.
11.
THE USE OF PARAXANTHINE TO IMPROVE PERFORMANCE IN VIDEO GAMERS
Disclosed herein is a method for increasing video game performance in a subject by administering to the subject with a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. Further disclosed herein is a method for enhancing mood of a subject during electronic gameplay or preventing decrease in mood of a subject during electronic game play comprising administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, administration of the composition to the subject decreases, or prevents the increase of, one or more of tension, depression, anger, fatigue and/or confusion in the subject during electronic game play relative to a subject who has not been administered the composition.
A61K 36/81 - Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
12.
1-methylxanthine-based bioactive composition and method of use thereof
The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises 1-methylxanthine and optionally other compounds that modulate the effects of 1-methylxanthine. Uses for the 1-methylxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Nutraceuticals for use as a dietary supplement for general health and well-being; dietary supplements for general health and well-being; nutraceuticals for use as an ingredient in the manufacture of dietary supplements for general health and well-being.
14.
THE USE OF PARAXANTHINE TO REDUCE EXERCISE-INDUCED MENTAL FATIGUE
Disclosed herein are compositions and methods for attenuating stress-induced mental fatigue in subject in need thereof by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further embodiments, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, fatigue attenuated by the instantly disclosed method is a result of physical stress on the subject. Physical stresses that may result in mental fatigue include, but are not limited to, periods of intense exercise.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutraceuticals for use as an ingredient in the manufacture of dietary supplements, namely, methylxanthines; all of the aforementioned goods containing caffeine Nutraceuticals for use as a dietary supplement; dietary supplements; all of the aforementioned goods containing caffeine
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutraceuticals for use as an ingredient in the manufacture of dietary supplements, namely, methylxanthines Nutraceuticals for use as a dietary supplement; dietary supplements
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutraceuticals for use as a dietary supplement; dietary
supplements; nutraceuticals for use as an ingredient in the
manufacture of dietary supplements.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Nutraceuticals for use as a dietary supplement for general health and well-being; dietary supplements, namely dietary and nutritional supplements for general health and well being; nutraceuticals for use as an ingredient in the manufacture of dietary supplements for general health and well being
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Nutraceuticals for use as an ingredient in the manufacture of dietary supplements, namely, methylxanthines Nutraceuticals for use as a dietary supplement; dietary supplements
20.
PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF
The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises paraxanthine and optionally other compounds that modulate the effects of paraxanthine. Uses for the paraxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
